Solventum (SOLV) board, executives and insiders

Jul 20, 2026
On July 16, 2026, the Board of Directors of Solventum Corporation (the “Company”) appointed Neil Zieselman to serve as Senior Vice President, Controller and Chief Accounting Officer of the Company, effective as of August 10, 2026. Mr. Zieselman is replacing Mary Wilcox in this role in connection with her previously announced retirement and will report directly to Wayde McMillan, the Company’s Chief Financial Officer. Mr. Zieselman will function as the Company’s Principal Accounting Officer for Securities and Exchange Commission (“SEC”) reporting purposes. Mr. Zieselman, age 50, joins the Company from Surgery Partners, Inc., where he has served as its Senior Vice President, Corporate Finance and Controller since May 2022. Prior to Surgery Partners, Inc., Mr.
Read the 8-K filing
May 27, 2026
On May 21, 2026, the Talent Committee (the “Committee”) of the Board of Directors of Solventum Corporation (the “Company”) adopted and approved the Solventum Executive Severance Plan and Summary Plan Description (the “Severance Plan”), effective June 1, 2026. The Severance Plan provides severance payments and benefits to certain eligible employees of the Company, including executive officers, in the event of an involuntary termination of employment other than for misconduct or a voluntary termination for good reason, subject to eligibility conditions and the execution of a severance agreement, which includes a release of claims.
Read the 8-K filing
Mar 24, 2026
(b) On March 20, 2026, Mary Wilcox informed Solventum Corporation (the “Company”) of her intent to retire and resign from her position as Chief Accounting Officer of the Company following a search for and appointment of her successor.
Read the 8-K filing
Oct 21, 2025
On October 21, 2025, Solventum Corporation (the “Company”) announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer of the Company, effective as of November 10, 2025. Ms. Knight will oversee all global commercial and R&D operations across the Company’s MedSurg, Dental Solutions and Health Information Systems segments and will report directly to CEO Bryan Hanson. In connection with Ms. Knight’s appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart the Company effective December 31, 2025. Upon execution and non-revocation of a general release of claims, Mr.
Read the 8-K filing
Nov 5, 2024
On October 30, 2024, the Talent Committee of the Board of Directors (the “Committee”) of Solventum Corporation (“Solventum”) approved and adopted the Solventum Executive Change in Control Severance Plan (the “CIC Severance Plan”), which is effective as of such date. Solventum’s Chief Executive Officer (“CEO”), Chief Financial Officer, Chief Accounting Officer, and other executives (the “Participants”) currently participate in Solventum’s Executive Severance Plan, the details of which were previously disclosed on Form 8-K filed with the SEC on April 4, 2024 (the “Severance Plan”). However, the Severance Plan does not provide enhanced severance benefits in the event of certain involuntary terminations that occur within a pre-defined period relative to a change in control. Accordingly, the Committee adopted the CIC Severance Plan to provide these enhanced severance benefits.
Read the 8-K filing
May 17, 2024
On May 13, 2024, the Talent Committee (the “Committee”) of the Board of Directors of Solventum Corporation (the “Company”), in connection with the award of restricted stock units (“RSUs”) and performance shares (“PSUs”) to certain executive officers and directors of the Company, approved new forms of restricted stock unit award agreements (the “RSU Award Agreements”) and a form of performance share units agreement (the “PSU Award Agreement”) under the Solventum 2024 Long-Term Incentive Plan, which forms are included as Exhibits 10.1, 10.2 and 10.3 to this Current Report on Form 8-K (the “Award Agreements”). The grant of RSUs and PSUs to the Company’s Chief Executive Officer and Chief Financial Officer approved by the Committee are set forth in the table below.
Read the 8-K filing
Apr 16, 2024
On April 12, 2024, the Board of Directors (the “Board”) of Solventum Corporation (the “Company”) elected Shirley A. Edwards to the Company’s Board, effective April 12, 2024. Ms. Edwards was a Partner at EY (formerly Ernst & Young LLP) from 2002 to 2022, most recently serving as a Global Client Service Partner from 2017 to 2022. Ms. Edwards will join the Board as a Class II director, and her term will expire with the terms of the other Class II directors at the 2026 annual meeting of stockholders. The Board has determined that Ms. Edwards is an independent director under the New York Stock Exchange listing standards. There was no arrangement or understanding between Ms. Edwards and any other persons, pursuant to which Ms. Edwards was appointed to serve on the Board. Additionally, there are no transactions between Ms.
Read the 8-K filing
Apr 4, 2024
Appointment of Officers In connection with the Distribution, as of the Effective Time, all of the executive officers of Solventum were removed and the following individuals became executive officers of Solventum, with the titles set forth in the table below: Bryan Hanson Chief Executive Officer Wayde McMillan Chief Financial Officer Marcela Kirberger Chief Legal Affairs Officer, Corporate Secretary Mary Wilcox Senior Vice President, Controller and Chief Accounting Officer Chris Barry Executive Vice President and Group President, Medical Solutions Amy Landucci Chief Information and Digital Officer Paul Harrington Chief Supply Chain Officer Tammy Gomez Chief Human Resources Officer Biographical information for Bryan Hanson, Wayde McMillan and Marcela Kirberger can be found in the Information Statement under the section entitled “Management.” This section is incorporated by reference into t…
Read the 8-K filing